Patents Assigned to Genentech
  • Therapeutic compounds and methods of use thereof
    Patent number: 11130726
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 28, 2021
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William Hemeon, Brian Salvatore Safina, Daniel Sutherlin
  • Biheteroaryl compounds and uses thereof
    Patent number: 11129832
    Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis, Terry Kellar, Wen Liu, Changyou Ma, Joseph P. Lyssikatos, Alan G. Olivero, Snahel Patel, Daniel Shore, Michael Siu
  • Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
    Patent number: 11130791
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Low Affinity Blood Brain Barrier Receptor Antibodies and Uses Thereof
    Publication number: 20210292440
    Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.
    Type: Application
    Filed: January 28, 2021
    Publication date: September 23, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Yu Zuchero, Yin Zhang
  • HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
    Publication number: 20210292435
    Abstract: The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscosity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 23, 2021
    Applicant: Genentech, Inc.
    Inventors: Nicholas J. ARMSTRONG, Mayumi N. BOWEN, Yuh-Fun MAA
  • METHODS FOR REMOVING A CONTAMINANT USING INDIGENOUS PROTEIN DISPLACEMENT ION EXCHANGE MEMBRANE CHROMATOGRAPHY
    Publication number: 20210284685
    Abstract: Methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant are described, which methods comprise the sequential steps of: (a) passing the composition through an ion exchange membrane, where the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and the at least one contaminant, and (b) recovering the purified polypeptide from the effluent.
    Type: Application
    Filed: January 20, 2021
    Publication date: September 16, 2021
    Applicant: Genentech, Inc.
    Inventors: Arick BROWN, Jerome BILL, Jr., Timothy TULLY, Christopher DOWD
  • METHODS OF TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20210284720
    Abstract: The invention provides methods of treating tauopathies with anti-Tau antibodies.
    Type: Application
    Filed: January 15, 2021
    Publication date: September 16, 2021
    Applicant: Genentech, Inc.
    Inventors: Geoffrey Kerchner, Edmond Teng
  • COMBINATION THERAPY FOR THE TREATMENT OF PANCREATIC CANCER
    Publication number: 20210283120
    Abstract: The subject matter described herein is directed to compositions comprising a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor that targets PDGFR?, S6 and STAT3 or a pharmaceutically acceptable salt thereof, and their use in treating pancreatic cancer. In another aspect, disclosed herein are methods of treating pancreatic cancer by administering a MEK inhibitor, or a pharmaceutically acceptable salt thereof, and a multi-kinase inhibitor, or a pharmaceutically acceptable salt thereof. In another aspect, the combination of cobimetinib, or a pharmaceutically acceptable salt thereof, and ponatinib or a pharmaceutically acceptable salt thereof is administered in a composition or the combination is administered separately to treat pancreatic cancer.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 16, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeff Settleman, Nisebita Sahu
  • KLOTHO BETA
    Publication number: 20210284753
    Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.
    Type: Application
    Filed: November 10, 2020
    Publication date: September 16, 2021
    Applicant: Genentech, Inc.
    Inventor: Luc Desnoyers
  • Multispecific antigen-binding proteins
    Patent number: 11116840
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 14, 2021
    Assignee: Genentech, Inc.
    Inventors: Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon
  • NAPHTHYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210277024
    Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 9, 2021
    Applicant: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
    Patent number: 11110087
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: September 7, 2021
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Compositions and methods for stabilizing protein-containing formulations
    Patent number: 11103584
    Abstract: The present invention relates to use of certain alkylglycoside compositions for the prevention of aggregation and oxidation of antibodies and other proteins in therapeutically useful formulations thereof.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 31, 2021
    Assignee: GENENTECH, INC.
    Inventors: Osigwe Esue, Vikas K. Sharma
  • Quaternary amine compounds and antibody-drug conjugates thereof
    Patent number: 11104673
    Abstract: This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 31, 2021
    Assignee: Genentech, Inc.
    Inventors: John A. Flygare, Thomas Pillow, Leanna Staben
  • SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210261568
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
  • METHODS OF PRODUCING TWO CHAIN PROTEINS IN PROKARYOTIC HOST CELLS
    Publication number: 20210261973
    Abstract: Provided herein are methods and host cells for producing a polypeptide containing two chains, such as an antibody, half-antibody, antibody fragment, or one-armed antibody. The methods and host cells allow for two-chain polypeptide production using expression of polynucleotides encoding the polypeptide chains from extra-chromosomal polynucleotide(s), and expression of one or more chaperone protein(s) (e.g., peptidyl-prolyl isomerases and/or protein disulfide oxidoreductases) from the host cell chromosome using non-native combination(s) of promoters and translational units encoding a chaperone protein.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Karthik VEERAVALLI, Rebekah MCKENNA
  • Inhibitors of IAP
    Patent number: 11096982
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: August 24, 2021
    Assignee: GENENTECH, INC.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Anti-transferrin receptor antibodies and methods of use
    Patent number: 11098129
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Genentech, Inc.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S Dennis, James A Ernst, Ryan J Watts, Gregory A Lazar
  • Process for the manufacturing of medicaments
    Patent number: 11098028
    Abstract: The present invention provides a process for the manufacture of a compound of formula VIIIa and salts forms of VIIIa where Rc is an aryl sulfonic acid
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: August 24, 2021
    Assignee: Genentech, Inc.
    Inventors: Jinguang Lin, Alexandra Chestakova, Wei Gu, Hans Iding, Jing Li, Xin Linghu, Patrik Meier, Chunbo Sha, Jeffrey Stults, Youchu Wang, Haiming Zhang, Jianqian Zhang, Tao Zhang
  • Label for a vial
    Patent number: D931370
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: September 21, 2021
    Assignee: Genentech, Inc.
    Inventors: Mahesh Khurana, Dominique Daniel Schall, Kai Zheng, Erin Susan Araj